Recent
quick returnPopular searches
live pathsNYSE · HEALTHCARE · Earnings & dividends
Next scheduled report in 58 days, last quarterly EPS, consensus estimates, payout status, and capital-return context for ABBV.
| Period | Actual EPS | Est. EPS | Surprise |
|---|---|---|---|
| Q4 | $0.98 | $0.99 | -1.4% |
| Q1 | $0.68 | $0.67 | +1.5% |
| Q2 | $0.82 | $0.79 | +3.8% |
| Q3 | $0.82 | $0.77 | +6.5% |
| Q4 | $0.82 | $0.82 | +0.0% |
| Q1 | $0.71 | $0.68 | +4.4% |
| Q2 | $0.82 | $0.76 | +7.9% |
| Q3 | $0.89 | $0.77 | +15.6% |
Most recent periods shown. Full history available via data providers.
Dividends and capital return
Dividend yield only makes sense next to earnings power. TECHi keeps payout ratio, yield, and ex-date on this page so income investors can read the cash return against EPS.
EPS beat history
Recent reported quarters are compared against the consensus estimate so the latest print is easy to read at a glance. Positive bars mean reported EPS cleared expectations; negative bars mark misses.
Recent quarters
$2.65 actual vs $2.67 est.
$2.71 actual vs $2.65 est.
$1.86 actual vs $1.78 est.
$2.97 actual vs $2.91 est.
$2.46 actual vs $2.40 est.
$2.16 actual vs $2.12 est.
Earnings call transcript
12 segments
Operator
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2026 Earnings Conference Call. Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior...
Elizabeth Shea
Senior Vice President, Investor Relations
Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President and Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and...
Rob Michael
Chairman and Chief Executive Officer
Thank you, Liz. Good morning, everyone, and thank you for joining us. AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio. We are delivering top-tier growth and continue to...
Jeff Stewart
Executive Vice President and Chief Commercial Officer
Thank you, Rob. I'll start with the quarterly results for immunology, which delivered total revenues of $7.3 billion reflecting impressive sales growth of $1 billion. Skyrizi total sales were $4.5 billion, up 29.2% on an operational basis, exceeding our...
Roopal Thakkar
Executive Vice President, Research and Development and Chief Scientific Officer
Thank you, Jeff. We continue to make good progress across our pipeline. I'll start with dermatology programs in immunology. As Jeff just mentioned, new data was presented at the recent AAD meeting, highlighting SKYRIZI's strong efficacy in genital and scalp...
Scott Reents
Executive Vice President and Chief Financial Officer
Thank you, Roopal. Starting with our first quarter results. We reported adjusted earnings per share of $2.65, which is $0.07 above our guidance midpoint. These results include a $0.41 unfavorable impact from acquired IPR&D expense. Total net revenues were $15...
Earnings desk view
AbbVie Inc has per-quarter EPS history available across recent reports, pairing the latest actual EPS with consensus estimates and valuation context. For real-time commentary on ABBV's next print, the news archive tracks every editorial reaction to earnings reports.
Payout history
Market data feed
| Ex-date | Amount | Record date | Payment date |
|---|---|---|---|
| $1.73 | |||
| $1.73 | |||
| $1.64 | |||
| $1.64 | |||
| $1.64 | |||
| $1.64 | |||
| $1.55 | |||
| $1.55 | |||
| $1.55 | |||
| $1.55 | |||
| $1.48 | |||
| $1.48 | |||
| $1.48 | |||
| $1.48 | |||
| $1.41 | |||
| $1.41 | |||
| $1.41 | |||
| $1.41 | |||
| $1.30 | |||
| $1.30 | |||
| $1.30 | |||
| $1.30 | |||
| $1.18 | — | — | |
| $1.18 |
Dividend safety read
A payout ratio above 100% means the dividend is being funded out of cash, debt, or asset sales rather than current earnings. That usually means either earnings need to recover or the payout deserves extra scrutiny.
Frequently asked
AbbVie Inc reports quarterly. Track the latest scheduled date and consensus estimate on TECHi's ABBV earnings page — updated whenever the company confirms the quarterly call.
AbbVie Inc's trailing earnings per share is approximately $2.05 based on the most recent fundamentals snapshot.
TECHi's ABBV earnings page covers the next scheduled report, the last several quarters of beats and misses, and editorial commentary tied to each release.
Beat / miss commentary for the most recent AbbVie Inc quarter is published on the TECHi ABBV earnings page. Subscribe to the markets newsletter for the morning brief on every print.
Yes — AbbVie Inc (ABBV) pays a dividend with a current yield of approximately 3.08%.
AbbVie Inc has a forward dividend yield of approximately 3.08% based on the most recent quote.
AbbVie Inc distributes approximately $6.74 per share annually based on the latest declared payout.
AbbVie Inc's payout ratio is approximately 3.29%, the share of earnings paid out as dividends. A lower ratio leaves more room for dividend growth.
TECHi's ABBV earnings and dividends page shows the live yield, payout history, ex-dividend dates, payout ratio, and dividend-safety commentary beside EPS history.
